TabsDetailsBasic DetailsDate Posted: Thursday, January 2, 2020Status: CompleteMedical Product: alpha-glucosidase inhibitor, amylin analog, biguanide, dipeptidyl peptidase-4 (DPP-4) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, injectable insulin, meglitinide analog, sulfonylurea, thiazolidinedioneHealth Outcome(s): exposure in pregnancyDescription: This report contains estimates of the prevalence of antidiabetic agent use among females 10 to 54 years of age who delivered a live-born infant between January 1, 2001 and December 31, 2013 in the Mini-Sentinel Distributed Database (MSDD). Results for antidiabetic agent use are also presented for a matched comparator cohort with no live-birth deliveries during the request period.Data from January 1, 2001 to December 31, 2013, from 15 Data Partners contributing to the MSDD were included in this report. This request was distributed to Data Partners on May 14, 2015. Read More Deliverables (1)Mini-Sentinel Modular Program Report: Summary of Antidiabetic Agent Use During PregnancyAdditional InformationAdditional DetailsFDA Center: CDERTime Period: January 1, 2001 - December 31, 2013Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: Females 10 to 54 years of ageData Sources: Mini-Sentinel Distributed Database (MSDD)Related Links: Use of Antidiabetic Drugs During Pregnancy among U.S. Women with Livebirth Deliveries in the Mini-Sentinel System
